ID   GLYA_ECOLI              Reviewed;         417 AA.
AC   P0A825; P00477;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   15-FEB-2017, entry version 105.
DE   RecName: Full=Serine hydroxymethyltransferase;
DE            Short=SHMT;
DE            Short=Serine methylase;
DE            EC=2.1.2.1;
GN   Name=glyA; OrderedLocusNames=b2551, JW2535;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RX   PubMed=6300791; DOI=10.1093/nar/11.7.2065;
RA   Plamann M.D., Stauffer L.T., Urbanowski M.L., Stauffer G.V.;
RT   "Complete nucleotide sequence of the E. coli glyA gene.";
RL   Nucleic Acids Res. 11:2065-2075(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=9205837; DOI=10.1093/dnares/4.2.91;
RA   Yamamoto Y., Aiba H., Baba T., Hayashi K., Inada T., Isono K.,
RA   Itoh T., Kimura S., Kitagawa M., Makino K., Miki T., Mitsuhashi N.,
RA   Mizobuchi K., Mori H., Nakade S., Nakamura Y., Nashimoto H.,
RA   Oshima T., Oyama S., Saito N., Sampei G., Satoh Y., Sivasundaram S.,
RA   Tagami H., Takahashi H., Takeda J., Takemoto K., Uehara K., Wada C.,
RA   Yamagata S., Horiuchi T.;
RT   "Construction of a contiguous 874-kb sequence of the Escherichia coli-
RT   K12 genome corresponding to 50.0-68.8 min on the linkage map and
RT   analysis of its sequence features.";
RL   DNA Res. 4:91-113(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   PROTEIN SEQUENCE OF 1-19.
RC   STRAIN=K12 / EMG2;
RX   PubMed=9298646; DOI=10.1002/elps.1150180807;
RA   Link A.J., Robison K., Church G.M.;
RT   "Comparing the predicted and observed properties of proteins encoded
RT   in the genome of Escherichia coli K-12.";
RL   Electrophoresis 18:1259-1313(1997).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-17.
RC   STRAIN=K12;
RX   PubMed=2034230; DOI=10.1007/BF00273586;
RA   Vasudevan S.G., Armarego W.L.F., Shaw D.C., Lilley P.E., Dixon N.E.,
RA   Poole R.K.;
RT   "Isolation and nucleotide sequence of the hmp gene that encodes a
RT   haemoglobin-like protein in Escherichia coli K-12.";
RL   Mol. Gen. Genet. 226:49-58(1991).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-11.
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RA   Pasquali C., Sanchez J.-C., Ravier F., Golaz O., Hughes G.J.,
RA   Frutiger S., Paquet N., Wilkins M., Appel R.D., Bairoch A.,
RA   Hochstrasser D.F.;
RL   Submitted (SEP-1994) to UniProtKB.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-7, AND FUNCTION AS A SERINE
RP   HYDROXYMETHYLTRANSFERASE.
RX   PubMed=6190704; DOI=10.1016/0378-1119(83)90059-8;
RA   Plamann M.D., Stauffer G.V.;
RT   "Characterization of the Escherichia coli gene for serine
RT   hydroxymethyltransferase.";
RL   Gene 22:9-18(1983).
RN   [9]
RP   MUTAGENESIS OF ARG-363 AND ARG-372.
RX   PubMed=7925461; DOI=10.1111/j.1432-1033.1994.00395.x;
RA   Delle Fratte S., Iurescia S., Angelaccio S., Bossa F., Schirch V.;
RT   "The function of arginine 363 as the substrate carboxyl-binding site
RT   in Escherichia coli serine hydroxymethyltransferase.";
RL   Eur. J. Biochem. 225:395-401(1994).
RN   [10]
RP   IDENTIFICATION BY 2D-GEL.
RX   PubMed=9298644; DOI=10.1002/elps.1150180805;
RA   VanBogelen R.A., Abshire K.Z., Moldover B., Olson E.R.,
RA   Neidhardt F.C.;
RT   "Escherichia coli proteome analysis using the gene-protein database.";
RL   Electrophoresis 18:1243-1251(1997).
RN   [11]
RP   MUTAGENESIS OF PRO-214; PRO-216; PRO-218; PRO-258 AND PRO-264, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12773539; DOI=10.1074/jbc.M303779200;
RA   Fu T.F., Boja E.S., Safo M.K., Schirch V.;
RT   "Role of proline residues in the folding of serine
RT   hydroxymethyltransferase.";
RL   J. Biol. Chem. 278:31088-31094(2003).
RN   [12]
RP   INDUCTION.
RX   PubMed=12624214; DOI=10.1099/mic.0.25841-0;
RA   Chirwa N.T., Herrington M.B.;
RT   "CsgD, a regulator of curli and cellulose synthesis, also regulates
RT   serine hydroxymethyltransferase synthesis in Escherichia coli K-12.";
RL   Microbiology 149:525-535(2003).
RN   [13]
RP   REACTION MECHANISM.
RX   PubMed=17341210; DOI=10.1042/BJ20061681;
RA   Malerba F., Bellelli A., Giorgi A., Bossa F., Contestabile R.;
RT   "The mechanism of addition of pyridoxal 5'-phosphate to Escherichia
RT   coli apo-serine hydroxymethyltransferase.";
RL   Biochem. J. 404:477-485(2007).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-54; LYS-250; LYS-285;
RP   LYS-354 AND LYS-375, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=K12 / JW1106, and K12 / MG1655 / ATCC 47076;
RX   PubMed=18723842; DOI=10.1074/mcp.M800187-MCP200;
RA   Zhang J., Sprung R., Pei J., Tan X., Kim S., Zhu H., Liu C.F.,
RA   Grishin N.V., Zhao Y.;
RT   "Lysine acetylation is a highly abundant and evolutionarily conserved
RT   modification in Escherichia coli.";
RL   Mol. Cell. Proteomics 8:215-225(2009).
RN   [15]
RP   MUTAGENESIS OF LEU-85 AND LEU-276, AND SUBUNIT.
RX   PubMed=19019081; DOI=10.1111/j.1742-4658.2008.06761.x;
RA   Florio R., Chiaraluce R., Consalvi V., Paiardini A., Catacchio B.,
RA   Bossa F., Contestabile R.;
RT   "The role of evolutionarily conserved hydrophobic contacts in the
RT   quaternary structure stability of Escherichia coli serine
RT   hydroxymethyltransferase.";
RL   FEBS J. 276:132-143(2009).
RN   [16]
RP   SUCCINYLATION AT LYS-62; LYS-242; LYS-250; LYS-277; LYS-293; LYS-331;
RP   LYS-346 AND LYS-354.
RC   STRAIN=K12;
RX   PubMed=21151122; DOI=10.1038/nchembio.495;
RA   Zhang Z., Tan M., Xie Z., Dai L., Chen Y., Zhao Y.;
RT   "Identification of lysine succinylation as a new post-translational
RT   modification.";
RL   Nat. Chem. Biol. 7:58-63(2011).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH SUBSTRATE
RP   ANALOGS AND PYRIDOXAL PHOSPHATE, AND MUTAGENESIS OF TYR-65.
RX   PubMed=10858298; DOI=10.1021/bi000032z;
RA   Contestabile R., Angelaccio S., Bossa F., Wright H.T., Scarsdale N.,
RA   Kazanina G., Schirch V.;
RT   "Role of tyrosine 65 in the mechanism of serine
RT   hydroxymethyltransferase.";
RL   Biochemistry 39:7492-7500(2000).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH SUBSTRATE
RP   ANALOGS, AND SUBUNIT.
RX   PubMed=10656824; DOI=10.1006/jmbi.1999.3453;
RA   Scarsdale J.N., Radaev S., Kazanina G., Schirch V., Wright H.T.;
RT   "Crystal structure at 2.4-A resolution of E. coli serine
RT   hydroxymethyltransferase in complex with glycine substrate and 5-
RT   formyl tetrahydrofolate.";
RL   J. Mol. Biol. 296:155-168(2000).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF MUTANT PHE-55 IN COMPLEX WITH
RP   PYRIDOXAL PHOSPHATE, MUTAGENESIS OF TYR-55 AND ARG-235, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19883126; DOI=10.1021/bi901568b;
RA   Vivoli M., Angelucci F., Ilari A., Morea V., Angelaccio S.,
RA   di Salvo M.L., Contestabile R.;
RT   "Role of a conserved active site cation-pi interaction in Escherichia
RT   coli serine hydroxymethyltransferase.";
RL   Biochemistry 48:12034-12046(2009).
CC   -!- FUNCTION: Catalyzes the reversible interconversion of serine and
CC       glycine with tetrahydrofolate (THF) serving as the one-carbon
CC       carrier. This reaction serves as the major source of one-carbon
CC       groups required for the biosynthesis of purines, thymidylate,
CC       methionine, and other important biomolecules. Also exhibits THF-
CC       independent aldolase activity toward beta-hydroxyamino acids,
CC       producing glycine and aldehydes, via a retro-aldol mechanism.
CC       Thus, is able to catalyze the cleavage of allothreonine and 3-
CC       phenylserine. Also catalyzes the irreversible conversion of 5,10-
CC       methenyltetrahydrofolate to 5-formyltetrahydrofolate.
CC       {ECO:0000269|PubMed:6190704}.
CC   -!- CATALYTIC ACTIVITY: 5,10-methylenetetrahydrofolate + glycine +
CC       H(2)O = tetrahydrofolate + L-serine.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7 uM for tetrahydrofolate {ECO:0000269|PubMed:12773539,
CC         ECO:0000269|PubMed:19883126};
CC         KM=140 uM for serine {ECO:0000269|PubMed:12773539,
CC         ECO:0000269|PubMed:19883126};
CC         KM=300 uM for serine {ECO:0000269|PubMed:12773539,
CC         ECO:0000269|PubMed:19883126};
CC   -!- PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion.
CC   -!- PATHWAY: Amino-acid biosynthesis; glycine biosynthesis; glycine
CC       from L-serine: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:10656824,
CC       ECO:0000269|PubMed:10858298, ECO:0000269|PubMed:19019081,
CC       ECO:0000269|PubMed:19883126}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-909080, EBI-909080;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- INDUCTION: By CsgD. {ECO:0000269|PubMed:12624214}.
CC   -!- SIMILARITY: Belongs to the SHMT family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; V00283; CAA23547.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC75604.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA16459.1; -; Genomic_DNA.
DR   EMBL; J01620; AAA23912.1; -; Genomic_DNA.
DR   PIR; A00559; XYECS.
DR   RefSeq; NP_417046.1; NC_000913.3.
DR   RefSeq; WP_000919159.1; NZ_LN832404.1.
DR   PDB; 1DFO; X-ray; 2.40 A; A/B/C/D=1-417.
DR   PDB; 1EQB; X-ray; 2.70 A; A/B/C/D=1-417.
DR   PDB; 3G8M; X-ray; 3.30 A; A=1-417.
DR   PDBsum; 1DFO; -.
DR   PDBsum; 1EQB; -.
DR   PDBsum; 3G8M; -.
DR   ProteinModelPortal; P0A825; -.
DR   SMR; P0A825; -.
DR   BioGrid; 4261314; 203.
DR   DIP; DIP-36205N; -.
DR   IntAct; P0A825; 7.
DR   MINT; MINT-7293373; -.
DR   STRING; 511145.b2551; -.
DR   SWISS-2DPAGE; P0A825; -.
DR   EPD; P0A825; -.
DR   PaxDb; P0A825; -.
DR   PRIDE; P0A825; -.
DR   EnsemblBacteria; AAC75604; AAC75604; b2551.
DR   EnsemblBacteria; BAA16459; BAA16459; BAA16459.
DR   GeneID; 947022; -.
DR   KEGG; ecj:JW2535; -.
DR   KEGG; eco:b2551; -.
DR   PATRIC; 32120501; VBIEscCol129921_2653.
DR   EchoBASE; EB0403; -.
DR   EcoGene; EG10408; glyA.
DR   eggNOG; ENOG4105C65; Bacteria.
DR   eggNOG; COG0112; LUCA.
DR   HOGENOM; HOG000239404; -.
DR   InParanoid; P0A825; -.
DR   KO; K00600; -.
DR   OMA; DANNPAV; -.
DR   PhylomeDB; P0A825; -.
DR   BioCyc; EcoCyc:GLYOHMETRANS-MONOMER; -.
DR   BioCyc; MetaCyc:GLYOHMETRANS-MONOMER; -.
DR   BRENDA; 2.1.2.1; 2026.
DR   BRENDA; 4.1.2.48; 2026.
DR   UniPathway; UPA00193; -.
DR   UniPathway; UPA00288; UER01023.
DR   EvolutionaryTrace; P0A825; -.
DR   PRO; PR:P0A825; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004372; F:glycine hydroxymethyltransferase activity; IDA:EcoCyc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IDA:EcoCyc.
DR   GO; GO:0008270; F:zinc ion binding; IDA:EcoliWiki.
DR   GO; GO:0019264; P:glycine biosynthetic process from serine; IDA:EcoCyc.
DR   GO; GO:0006546; P:glycine catabolic process; IMP:EcoCyc.
DR   GO; GO:0006565; P:L-serine catabolic process; IDA:EcoCyc.
DR   GO; GO:0035999; P:tetrahydrofolate interconversion; IEA:UniProtKB-UniPathway.
DR   CDD; cd00378; SHMT; 1.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   HAMAP; MF_00051; SHMT; 1.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_major_sub2.
DR   InterPro; IPR001085; Ser_HO-MeTrfase.
DR   InterPro; IPR019798; Ser_HO-MeTrfase_PLP_BS.
DR   PANTHER; PTHR11680; PTHR11680; 1.
DR   Pfam; PF00464; SHMT; 1.
DR   PIRSF; PIRSF000412; SHMT; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   PROSITE; PS00096; SHMT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Amino-acid biosynthesis; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; One-carbon metabolism;
KW   Pyridoxal phosphate; Reference proteome; Transferase.
FT   CHAIN         1    417       Serine hydroxymethyltransferase.
FT                                /FTId=PRO_0000113573.
FT   REGION      125    127       Substrate binding.
FT   REGION      355    357       Substrate binding.
FT   BINDING      35     35       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING      55     55       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING      57     57       Substrate.
FT   BINDING      64     64       Substrate.
FT   BINDING      65     65       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING      99     99       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING     121    121       Substrate; via carbonyl oxygen.
FT   BINDING     175    175       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING     203    203       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING     228    228       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING     235    235       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING     246    246       Substrate.
FT   BINDING     263    263       Pyridoxal phosphate; via amide nitrogen
FT                                and carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   BINDING     363    363       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:10858298,
FT                                ECO:0000269|PubMed:19883126}.
FT   SITE         55     55       Transaldimination and stability.
FT   SITE        235    235       Transaldimination and stability.
FT   MOD_RES      54     54       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18723842}.
FT   MOD_RES      62     62       N6-succinyllysine.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     229    229       N6-(pyridoxal phosphate)lysine.
FT   MOD_RES     242    242       N6-succinyllysine.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     250    250       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:18723842}.
FT   MOD_RES     250    250       N6-succinyllysine; alternate.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     277    277       N6-succinyllysine.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     285    285       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18723842}.
FT   MOD_RES     293    293       N6-succinyllysine.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     331    331       N6-succinyllysine.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     346    346       N6-succinyllysine.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     354    354       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:18723842}.
FT   MOD_RES     354    354       N6-succinyllysine; alternate.
FT                                {ECO:0000269|PubMed:21151122}.
FT   MOD_RES     375    375       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18723842}.
FT   MUTAGEN      55     55       Y->F: 50 and 15-fold increase in the
FT                                affinity for serine and tetrahydrofolate,
FT                                respectively, and 4-fold decrease in the
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:19883126}.
FT   MUTAGEN      65     65       Y->F: Decrease in catalytic activity.
FT                                {ECO:0000269|PubMed:10858298}.
FT   MUTAGEN      85     85       L->A: Alteration of the dimer-monomer
FT                                equilibrium accompanied by minor changes
FT                                in the catalytic properties and whitout
FT                                any significant change of tertiary
FT                                structure. In the monomeric state; when
FT                                associated with A-276.
FT                                {ECO:0000269|PubMed:19019081}.
FT   MUTAGEN     214    214       P->A: No significant difference in
FT                                catalytic efficiency and affinity
FT                                compared to the wild-type.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     214    214       P->G: No significant difference in
FT                                catalytic efficiency and affinity
FT                                compared to the wild-type.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     216    216       P->A: No significant difference in
FT                                catalytic efficiency and affinity
FT                                compared to the wild-type. Alteration in
FT                                the folding rate.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     216    216       P->G: Important decrease in affinity and
FT                                catalytic efficiency. Severely
FT                                compromised in folding into a
FT                                catalytically competent enzyme.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     218    218       P->A: No significant difference in
FT                                catalytic efficiency and affinity
FT                                compared to the wild-type.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     218    218       P->G: No significant difference in
FT                                catalytic efficiency and affinity
FT                                compared to the wild-type.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     235    235       R->K: 1500- and 20-fold increase in the
FT                                affinity for serine and tetrahydrofolate,
FT                                respectively, and 15-fold decrease in the
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:19883126}.
FT   MUTAGEN     235    235       R->L: 450- and 11-fold increase in the
FT                                affinity for serine and tetrahydrofolate,
FT                                respectively, and 60-fold decrease in the
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:19883126}.
FT   MUTAGEN     235    235       R->Q: 900- and 17-fold increase in the
FT                                affinity for serine and tetrahydrofolate,
FT                                respectively, and 30-fold decrease in the
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:19883126}.
FT   MUTAGEN     258    258       P->A: Important decrease in affinity and
FT                                catalytic efficiency. Reduced thermal
FT                                stability. {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     258    258       P->G: Important decrease in affinity and
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     264    264       P->A: Important decrease in affinity and
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     264    264       P->G: Important decrease in affinity and
FT                                catalytic efficiency.
FT                                {ECO:0000269|PubMed:12773539}.
FT   MUTAGEN     276    276       L->A: Alteration of the dimer-monomer
FT                                equilibrium accompanied by minor changes
FT                                in the catalytic properties and whitout
FT                                any significant change of tertiary
FT                                structure. In the monomeric state; when
FT                                associated with A-85.
FT                                {ECO:0000269|PubMed:19019081}.
FT   MUTAGEN     363    363       R->A: It does not bind serine and glycine
FT                                and shows no activity with serine as the
FT                                substrate. {ECO:0000269|PubMed:7925461}.
FT   MUTAGEN     363    363       R->K: Exhibits only 0.03% of the
FT                                catalytic activity of the wild-type and a
FT                                15-fold reduction in affinity for glycine
FT                                and serine. {ECO:0000269|PubMed:7925461}.
FT   MUTAGEN     372    372       R->A: No significant difference compared
FT                                to the wild-type.
FT                                {ECO:0000269|PubMed:7925461}.
FT   MUTAGEN     372    372       R->K: No significant difference compared
FT                                to the wild-type.
FT                                {ECO:0000269|PubMed:7925461}.
FT   HELIX         8     11       {ECO:0000244|PDB:1DFO}.
FT   HELIX        13     28       {ECO:0000244|PDB:1DFO}.
FT   STRAND       29     31       {ECO:0000244|PDB:1DFO}.
FT   HELIX        41     47       {ECO:0000244|PDB:1DFO}.
FT   HELIX        50     53       {ECO:0000244|PDB:1DFO}.
FT   STRAND       62     66       {ECO:0000244|PDB:1DFO}.
FT   HELIX        69     86       {ECO:0000244|PDB:1DFO}.
FT   STRAND       89     92       {ECO:0000244|PDB:1DFO}.
FT   HELIX        98    109       {ECO:0000244|PDB:1DFO}.
FT   STRAND      115    119       {ECO:0000244|PDB:1DFO}.
FT   TURN        121    124       {ECO:0000244|PDB:1DFO}.
FT   HELIX       127    129       {ECO:0000244|PDB:1DFO}.
FT   HELIX       135    139       {ECO:0000244|PDB:1DFO}.
FT   STRAND      140    145       {ECO:0000244|PDB:1DFO}.
FT   STRAND      149    152       {ECO:0000244|PDB:1DFO}.
FT   HELIX       155    165       {ECO:0000244|PDB:1DFO}.
FT   STRAND      168    173       {ECO:0000244|PDB:1DFO}.
FT   HELIX       183    192       {ECO:0000244|PDB:1DFO}.
FT   STRAND      196    200       {ECO:0000244|PDB:1DFO}.
FT   TURN        202    204       {ECO:0000244|PDB:1DFO}.
FT   HELIX       205    209       {ECO:0000244|PDB:1DFO}.
FT   TURN        217    219       {ECO:0000244|PDB:1DFO}.
FT   STRAND      220    229       {ECO:0000244|PDB:1DFO}.
FT   STRAND      237    243       {ECO:0000244|PDB:1DFO}.
FT   HELIX       246    256       {ECO:0000244|PDB:1DFO}.
FT   TURN        257    260       {ECO:0000244|PDB:1DFO}.
FT   HELIX       266    278       {ECO:0000244|PDB:1DFO}.
FT   HELIX       282    304       {ECO:0000244|PDB:1DFO}.
FT   HELIX       310    312       {ECO:0000244|PDB:1DFO}.
FT   STRAND      315    322       {ECO:0000244|PDB:1DFO}.
FT   HELIX       324    326       {ECO:0000244|PDB:1DFO}.
FT   HELIX       330    339       {ECO:0000244|PDB:1DFO}.
FT   TURN        356    358       {ECO:0000244|PDB:1DFO}.
FT   STRAND      360    365       {ECO:0000244|PDB:1DFO}.
FT   HELIX       367    371       {ECO:0000244|PDB:1DFO}.
FT   HELIX       376    391       {ECO:0000244|PDB:1DFO}.
FT   TURN        392    394       {ECO:0000244|PDB:1DFO}.
FT   HELIX       396    412       {ECO:0000244|PDB:1DFO}.
FT   STRAND      415    417       {ECO:0000244|PDB:1DFO}.
SQ   SEQUENCE   417 AA;  45317 MW;  13E5558E99938539 CRC64;
     MLKREMNIAD YDAELWQAME QEKVRQEEHI ELIASENYTS PRVMQAQGSQ LTNKYAEGYP
     GKRYYGGCEY VDIVEQLAID RAKELFGADY ANVQPHSGSQ ANFAVYTALL EPGDTVLGMN
     LAHGGHLTHG SPVNFSGKLY NIVPYGIDAT GHIDYADLEK QAKEHKPKMI IGGFSAYSGV
     VDWAKMREIA DSIGAYLFVD MAHVAGLVAA GVYPNPVPHA HVVTTTTHKT LAGPRGGLIL
     AKGGSEELYK KLNSAVFPGG QGGPLMHVIA GKAVALKEAM EPEFKTYQQQ VAKNAKAMVE
     VFLERGYKVV SGGTDNHLFL VDLVDKNLTG KEADAALGRA NITVNKNSVP NDPKSPFVTS
     GIRVGTPAIT RRGFKEAEAK ELAGWMCDVL DSINDEAVIE RIKGKVLDIC ARYPVYA
//
